Your browser is no longer supported. Please, upgrade your browser.
Settings
STRO [NASD]
Sutro Biopharma, Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own0.70% Shs Outstand45.91M Perf Week-5.95%
Market Cap853.78M Forward P/E- EPS next Y-2.30 Insider Trans-2.26% Shs Float40.72M Perf Month-9.31%
Income-32.10M PEG- EPS next Q-0.48 Inst Own98.40% Short Float9.07% Perf Quarter-26.82%
Sales42.70M P/S19.99 EPS this Y59.40% Inst Trans2.81% Short Ratio7.69 Perf Half Y38.58%
Book/sh6.69 P/B2.88 EPS next Y0.80% ROA- Target Price31.83 Perf Year100.52%
Cash/sh5.68 P/C3.40 EPS next 5Y- ROE- 52W Range7.06 - 28.30 Perf YTD-11.15%
Dividend- P/FCF- EPS past 5Y- ROI-19.90% 52W High-31.84% Beta-
Dividend %- Quick Ratio11.70 Sales past 5Y- Gross Margin- 52W Low173.23% ATR1.34
Employees191 Current Ratio11.70 Sales Q/Q104.20% Oper. Margin- RSI (14)42.59 Volatility6.35% 6.62%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.53 Prev Close18.52
ShortableYes LT Debt/Eq0.08 EarningsMar 18 BMO Payout- Avg Volume480.11K Price19.29
Recom1.70 SMA20-3.54% SMA50-10.40% SMA20010.08% Volume254,697 Change4.16%
Dec-03-20Initiated Stifel Buy $25
Sep-02-20Initiated Jefferies Buy $21
Jul-16-20Initiated Wells Fargo Overweight $18
Jan-13-20Initiated SunTrust Buy $18
Oct-07-19Initiated BTIG Research Buy $19
Jul-18-19Initiated Deutsche Bank Buy $22
Apr-29-19Initiated H.C. Wainwright Buy $18
Oct-22-18Initiated Wedbush Outperform $20
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated JMP Securities Mkt Outperform $28
May-07-21 08:25AM  
07:00AM  
Apr-20-21 07:00AM  
Apr-19-21 04:47PM  
Apr-15-21 07:00AM  
Apr-08-21 07:00AM  
Mar-22-21 10:31AM  
07:00AM  
Mar-18-21 08:35AM  
07:00AM  
Mar-12-21 08:30AM  
Mar-08-21 12:30PM  
Feb-23-21 07:00AM  
Jan-21-21 07:00AM  
Jan-05-21 07:00AM  
Dec-11-20 04:01PM  
Dec-08-20 09:10PM  
Dec-07-20 04:00PM  
10:00AM  
Dec-04-20 06:22PM  
12:59PM  
07:43AM  
Dec-03-20 04:30PM  
01:09PM  
Dec-01-20 07:00AM  
Nov-24-20 07:00AM  
Nov-18-20 07:00AM  
Nov-09-20 09:49AM  
Nov-05-20 07:00AM  
Nov-03-20 01:33PM  
Oct-12-20 12:10PM  
Sep-21-20 07:00AM  
Sep-10-20 07:20AM  
Sep-09-20 04:01PM  
Sep-04-20 07:27AM  
Sep-03-20 04:27PM  
07:55AM  
07:00AM  
Sep-02-20 04:12PM  
10:22AM  
Aug-25-20 07:00AM  
Aug-11-20 07:00AM  
Aug-10-20 05:00PM  
Aug-06-20 12:15PM  
07:00AM  
Aug-05-20 12:30PM  
Jun-30-20 11:06PM  
Jun-22-20 07:00AM  
Jun-11-20 02:34PM  
Jun-09-20 07:00AM  
Jun-08-20 06:06PM  
01:25PM  
Jun-03-20 04:49PM  
May-27-20 08:46AM  
May-25-20 03:20PM  
May-21-20 07:15AM  
07:00AM  
May-14-20 04:01PM  
May-13-20 11:25AM  
May-12-20 04:45PM  
May-11-20 11:55PM  
04:15PM  
Apr-27-20 12:01AM  
Apr-20-20 04:35PM  
Apr-13-20 05:00PM  
11:01AM  
Mar-26-20 09:20AM  
07:00AM  
Mar-16-20 08:35AM  
07:00AM  
Mar-12-20 07:00AM  
Mar-04-20 07:00AM  
Feb-06-20 01:13PM  
Feb-05-20 07:30AM  
Jan-09-20 07:00AM  
Jan-08-20 09:26AM  
Dec-19-19 04:46PM  
Nov-19-19 07:00AM  
Nov-08-19 10:57AM  
07:00AM  
Oct-30-19 01:59PM  
Oct-29-19 07:32AM  
07:00AM  
Oct-27-19 12:56PM  
Oct-16-19 04:35PM  
Oct-08-19 07:00AM  
Sep-04-19 07:00AM  
Sep-03-19 10:32AM  
Aug-14-19 06:15AM  
Aug-08-19 07:00AM  
Jul-31-19 12:52PM  
Jul-04-19 04:08PM  
Jun-24-19 04:05PM  
Jun-18-19 07:00AM  
Jun-15-19 06:00AM  
May-16-19 09:02AM  
May-15-19 07:00AM  
Apr-08-19 05:42PM  
Apr-04-19 07:00AM  
Apr-01-19 05:00AM  
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEWELL WILLIAM JCEOJan 29Option Exercise0.0013,7500192,410Feb 01 05:56 PM
MOLINA ARTURO MDChief Medical OfficerJan 29Option Exercise0.005,250022,966Feb 01 05:55 PM
Hallam TrevorChief Scientific OfficerJan 29Option Exercise0.005,250061,367Feb 01 05:55 PM
FITZPATRICK LINDA AChief People & Comm. OfficerJan 29Option Exercise0.008,250023,866Feb 01 05:54 PM
Shabbir AnikChief Technical Ops. OfficerJan 29Option Exercise0.004,500015,765Feb 01 05:53 PM
ALBINI EDWARD CCFO and SecretaryJan 29Option Exercise0.005,250016,326Feb 01 05:48 PM
Hallam TrevorChief Scientific OfficerJan 26Option Exercise4.362,39310,43358,510Jan 27 05:04 PM
Petree Daniel HDirectorJan 26Option Exercise4.364,13218,0167,988Jan 27 05:05 PM
Hallam TrevorChief Scientific OfficerJan 26Sale25.712,39361,52856,117Jan 27 05:04 PM
FITZPATRICK LINDA AChief People & Comm. OfficerJan 19Option Exercise4.361,6527,20315,616Jan 20 05:21 PM
Hallam TrevorChief Scientific OfficerJan 14Option Exercise4.3619,40584,60656,117Jan 15 06:10 PM
Hallam TrevorChief Scientific OfficerDec 28Option Exercise4.362,39310,43339,105Dec 29 05:00 PM
Hallam TrevorChief Scientific OfficerDec 28Sale22.372,39353,53036,712Dec 29 05:00 PM
Hallam TrevorChief Scientific OfficerNov 27Option Exercise4.362,39310,43339,105Nov 30 05:14 PM
Hallam TrevorChief Scientific OfficerNov 27Sale17.012,39340,71336,712Nov 30 05:14 PM
Hallam TrevorChief Scientific OfficerNov 05Option Exercise4.3616,75173,03453,463Nov 06 05:08 PM
Hallam TrevorChief Scientific OfficerNov 05Sale15.0016,751251,26536,712Nov 06 05:08 PM
Hallam TrevorChief Scientific OfficerOct 05Option Exercise4.369,18240,03436,712Oct 06 04:54 PM
Hallam TrevorChief Scientific OfficerSep 28Sale10.2697510,00727,530Sep 28 05:55 PM
Hallam TrevorChief Scientific OfficerSep 25Option Exercise0.0017,906030,886Sep 28 05:55 PM
FITZPATRICK LINDA AChief People & Comm. OfficerSep 25Option Exercise0.007,576016,583Sep 28 05:54 PM
ALBINI EDWARD CCFO and SecretarySep 25Option Exercise0.007,174013,556Sep 28 05:52 PM
Shabbir AnikChief Technical Ops. OfficerSep 25Option Exercise0.008,609014,241Sep 28 05:53 PM
NEWELL WILLIAM JCEOSep 25Option Exercise0.0025,2520191,879Sep 28 05:57 PM
MOLINA ARTURO MDChief Medical OfficerSep 25Option Exercise0.008,609020,692Sep 28 05:56 PM
Freund John GordonDirectorSep 18Sale12.00400,0004,800,000560,053Sep 22 04:56 PM
Freund John GordonDirectorSep 11Sale10.00500,0005,000,000960,053Sep 15 05:15 PM
Hallam TrevorChief Scientific OfficerAug 26Sale9.049758,81816,790Aug 27 05:04 PM
Freund John GordonDirectorAug 19Sale8.72500,0004,360,0001,460,053Aug 21 05:18 PM
Hallam TrevorChief Science OfficerJul 27Sale8.069757,85817,765Jul 28 05:08 PM
Hallam TrevorChief Science OfficerMay 26Sale10.009759,75319,715May 27 06:38 PM
NEWELL WILLIAM JCEOMay 14Buy7.7564,516499,999166,627May 14 05:29 PM
MOLINA ARTURO MDChief Medical OfficerMay 14Buy7.756,45149,99512,083May 14 05:27 PM
FITZPATRICK LINDA AChief People & Comm. OfficerMay 14Buy7.753,22524,9949,007May 14 05:26 PM